Literature DB >> 27342370

Expression of cyclooxygenase 2 and vascular endothelial growth factor in gastric carcinoma: Relationship with clinicopathological parameters.

Nesreen H Hafez1, Neveen S Tahoun2.   

Abstract

BACKGROUND: Gastric cancer is one of the most common cancers and the second most common cause of cancer-related death worldwide. Identification of specific prognostic indicators might allow a better prognostic stratification and more effective therapy. AIM: To assess the expression and relationship between COX-2 and VEGF protein in gastric adenocarcinoma and whether these markers are useful in predicting clinicopathological prognostic parameters.
MATERIALS AND METHODS: The study included 83 formalin-fixed paraffin embedded tissue samples of excised gastric adenocarcinoma and 20 non tumorous tissue controls. The slides were subjected to COX-2 and VEGF immunohistochemical staining using a streptavidin-biotinperoxidase according to the manufacturer's protocol. The results were assessed independently by two pathologists. The relationships among COX-2 and VEGF expression and clinicopathological parameters were statistically analyzed.
RESULTS: COX-2 and VEGF expressions were obviously higher in carcinoma tissues compared to normal mucosae (p<0.001). The expression rate of COX-2 was 54.2% and of VEGF was 68.7%. COX-2 positive tumors were significantly correlated with Lauren classification, tumor depth and Helicobacter pylori infection (p<0.001, p=0.008, p=0.035). VEGF was significantly associated with lymph node metastasis and tumor depth (p<0.001). There was a positive association between VEGF and COX-2 expression in gastric adenocarcinoma (Kappa value=0.55).
CONCLUSION: In gastric adenocarcinoma, COX-2 expression might serve as a powerful indicator for intestinal type carcinoma, locally advanced disease and H. pylori infection, while VEGF was related to loco-regional progression. COX-2 might be involved in the development of angiogenesis in gastric carcinoma through VEGF upregulation.
Copyright © 2016 National Cancer Institute, Cairo University. Production and hosting by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  COX-2; Gastric adenocarcinoma; IHC; VEGF

Mesh:

Substances:

Year:  2016        PMID: 27342370     DOI: 10.1016/j.jnci.2016.05.005

Source DB:  PubMed          Journal:  J Egypt Natl Canc Inst        ISSN: 1110-0362


  5 in total

1.  Plasma VEGF and Leptin Values in Patients With Gastric Intestinal Metaplasia and Metabolic Syndrome.

Authors:  George Pappas-Gogos; Kostas Tepelenis; Anna Goussia; Constantinos Tellis; Fotis Fousekis; Georgios K Glantzounis; Konstantinos Vlachos
Journal:  Front Oncol       Date:  2022-05-31       Impact factor: 5.738

2.  Insights into gastric neuroendocrine tumors burden.

Authors:  Taíssa Maíra Thomaz Araújo; Williams Fernandes Barra; André Salim Khayat; Paulo Pimentel de Assumpção
Journal:  Chin J Cancer Res       Date:  2017-04       Impact factor: 5.087

Review 3.  Immunological Approaches Towards Cancer and Inflammation: A Cross Talk.

Authors:  Xinglong Qu; Ying Tang; Shucheng Hua
Journal:  Front Immunol       Date:  2018-03-20       Impact factor: 7.561

4.  miR-148a inhibits early relapsed colorectal cancers and the secretion of VEGF by indirectly targeting HIF-1α under non-hypoxia/hypoxia conditions.

Authors:  Hsiang-Lin Tsai; Zhi-Feng Miao; Yi-Ting Chen; Ching-Wen Huang; Yung-Sung Yeh; I-Ping Yang; Jaw-Yuan Wang
Journal:  J Cell Mol Med       Date:  2019-03-04       Impact factor: 5.310

Review 5.  Issues of origin, morphology and clinical significance of tumor microvessels in gastric cancer.

Authors:  Marina A Senchukova
Journal:  World J Gastroenterol       Date:  2021-12-28       Impact factor: 5.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.